Skip to content

Treatment of Anxiety Disorders for Children and Adolescents in Regular Outpatient Clinics

Treatment of Anxiety Disorders for Children and Adolescents in Regular Outpatient Clinics (TADCAROC)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02218996
Acronym
TADCAROC
Enrollment
260
Registered
2014-08-18
Start date
2014-08-31
Completion date
2029-12-31
Last updated
2024-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety Disorders

Keywords

Anxiety, Children, Adolescent, Effectiveness, Outpatient

Brief summary

The purpose of this study is to examine the content of the treatment being delivered for anxiety disorders for children and adolescents in the regular outpatient clinics in western Norway. The study will also collect data before and after treatment to evaluate the result of the treatment. Furthermore, as part of the study we aim to collect normative data on two questionnaires used to identify anxiety symptoms and the extent to which anxiety interfere with daily functioning. We also aim to develop a quality indicator for anxiety treatment that can be used to monitor treatment in the regular outpatient service, based on the results of the current study.

Interventions

Regular psychosocial treatment in clinical outpatient service.

Sponsors

Helse Vest
CollaboratorOTHER
Helse Stavanger HF
Lead SponsorOTHER_GOV

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
7 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of an anxiety disorder (including PTSD and OCD) based on the diagnostic interview ADIS (ADIS-C/P; Silverman & Albano, 1996). * The anxiety disorder is the patients primary diagnosis. * Informed concent is given.

Exclusion criteria

* The patient is in need for other primary treatment intervention (e.g., psychosis, suicidality risk)

Design outcomes

Primary

MeasureTime frameDescription
The Anxiety Disorder Interview Schedule for Diagnostic and Statistical Manual (DSM-IV), child and parent versions (ADIS- C/P; Silverman & Albano, 1996).The primary outcome measure will be administered pre-treatment, post treatment (an expected average of 20 weeks) and at ten year follow-up.Diagnostic interview for anxiety disorders and other comorbid disorders. For the 10-year follow-up we anticipate to use another version of the diagnostic interview schedule based on revised diagnostic criteria for anxiety disorders.

Secondary

MeasureTime frame
The Screen for Child Anxiety Related Emotional Disorders (SCARED; Birmaher et al., 1999).This outcome measure will be administered pre-treatment and post treatment (an expected average of 20 weeks).
Spence Children's Anxiety Scale (SCAS; Spence, 1998)This outcome measure will be administered pre-treatment and post treatment (an expected average of 20 weeks).
Children's Anxiety Life Interference Scale (CALIS; Lyneham et al., 2013)This outcome measure will be administered pre-treatment and post treatment (an expected average of 20 weeks).
Short Mood & Feeling Questionaire (SMFQ; Angold et al., 1995).This outcome measure will be administered pre-treatment and post treatment (an expected average of 20 weeks)
Clinical Global Impressions (CGI; Guy, 1976).The outcome measure will be administered pre-treatment, post treatment (an expected average of 20 weeks) and at ten year follow-up.
The Strengths and Difficulties Questionnaire (SDQ; Goodman, 1997)This outcome measure will be administered pre-treatment and post treatment (an expected average of 20 weeks)

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026